Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$105.90
0.0%
$112.52
$89.67
$121.64
$183.76B0.765.32 million shs3.61 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$734.97
-2.8%
$761.06
$419.80
$800.78
$698.52B0.372.63 million shs4.60 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$123.05
-0.8%
$127.20
$75.56
$138.28
$552.19B0.433.91 million shs5.93 million shs
Novartis AG stock logo
NVS
Novartis
$97.27
-0.1%
$97.48
$92.19
$108.78
$198.82B0.531.91 million shs1.05 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.81
+0.4%
$26.88
$25.20
$40.37
$157.48B0.6341.90 million shs60.57 million shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-0.04%-1.52%-4.88%-5.56%-5.26%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.77%+0.20%-5.33%+10.08%+70.45%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.72%-2.98%-3.08%+8.25%+193.45%
Novartis AG stock logo
NVS
Novartis
-0.09%-0.19%+3.04%-6.24%-6.89%
Pfizer Inc. stock logo
PFE
Pfizer
+0.40%+9.57%+2.13%+3.27%-27.67%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9967 of 5 stars
3.35.04.24.53.22.52.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.716 of 5 stars
2.43.02.54.02.61.73.1
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.2513 of 5 stars
1.43.02.50.02.50.03.1
Novartis AG stock logo
NVS
Novartis
3.2585 of 5 stars
2.05.02.50.03.10.02.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9788 of 5 stars
4.23.04.24.83.71.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.67
Moderate Buy$121.5014.73% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$757.953.13% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.75
Moderate Buy$133.608.57% Upside
Novartis AG stock logo
NVS
Novartis
2.00
Hold$115.0018.23% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.0029.45% Upside

Current Analyst Ratings

Latest PFE, LLY, ABT, NVO, and NVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$900.00 ➝ $1,001.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$850.00 ➝ $900.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$850.00 ➝ $892.00
4/30/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00 ➝ $885.00
4/24/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$124.00
4/24/2024
Novartis AG stock logo
NVS
Novartis
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$114.00 ➝ $116.00
4/22/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$141.00 ➝ $140.00
4/18/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$128.00 ➝ $125.00
4/18/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.58$6.36 per share16.65$22.36 per share4.74
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.47$7.41 per share99.12$13.57 per share54.16
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$33.71B16.38$2.99 per share41.19$3.45 per share35.67
Novartis AG stock logo
NVS
Novartis
$47.73B4.17$11.10 per share8.76$19.45 per share5.00
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.69$2.99 per share9.31$15.81 per share1.76

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2132.9920.682.5513.96%20.32%10.59%7/18/2024 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$6.79108.2439.451.5017.08%56.98%10.94%8/13/2024 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$12.15B$2.9042.4330.092.0736.56%92.21%29.87%8/8/2024 (Estimated)
Novartis AG stock logo
NVS
Novartis
$14.85B$7.4113.1311.951.5631.33%32.15%13.59%7/16/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A10.261.18-0.56%8.58%3.70%8/6/2024 (Estimated)

Latest PFE, LLY, ABT, NVO, and NVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
4/30/2024Q1 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.53$2.58+$0.05$2.68$8.94 billion$8.77 billion      
4/17/2024Q1 24
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.96$0.98+$0.02$1.26$9.88 billion$9.96 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.08%+12.31%68.54%53 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.71%+15.15%76.58%10 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.331.08%+16.52%45.86%1 Years
Novartis AG stock logo
NVS
Novartis
$2.432.50%+4.26%32.79%4 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.04%+2.57%N/A 15 Years

Latest PFE, LLY, ABT, NVO, and NVS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
2/16/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.551.9%4/12/20244/15/20245/15/2024
3/1/2024
Novartis AG stock logo
NVS
Novartis
annual$3.77723.1%3/7/20243/8/20243/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.35
1.64
1.16
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.90
1.35
0.73
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.19
0.82
0.64
Novartis AG stock logo
NVS
Novartis
0.43
0.90
0.71
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Novartis AG stock logo
NVS
Novartis
13.12%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
1.10%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Novartis AG stock logo
NVS
Novartis
0.01%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.72 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.41 million949.17 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
63,3704.49 billion4.48 billionOptionable
Novartis AG stock logo
NVS
Novartis
76,0572.04 billion2.04 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE, LLY, NVO, ABT, and NVS Headlines

SourceHeadline
Sapient Capital LLC Takes $1.63 Million Position in Pfizer Inc. (NYSE:PFE)Sapient Capital LLC Takes $1.63 Million Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 4 at 12:45 PM
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
fool.com - May 4 at 5:17 AM
FY2025 Earnings Estimate for Pfizer Inc. Issued By Leerink Partnrs (NYSE:PFE)FY2025 Earnings Estimate for Pfizer Inc. Issued By Leerink Partnrs (NYSE:PFE)
americanbankingnews.com - May 4 at 4:38 AM
Pfizer Inc. (PFE) Q1 2024 Earnings Call TranscriptPfizer Inc. (PFE) Q1 2024 Earnings Call Transcript
msn.com - May 3 at 11:19 PM
Buy Rating Affirmed for Pfizer Amid Strong Q1 Performance and Strategic Cost SavingsBuy Rating Affirmed for Pfizer Amid Strong Q1 Performance and Strategic Cost Savings
markets.businessinsider.com - May 3 at 11:19 PM
Pfizer (NYSE:PFE) Stock Price Down 0.3%Pfizer (NYSE:PFE) Stock Price Down 0.3%
marketbeat.com - May 3 at 9:55 PM
Amgens peek at its GLP-1 drug trial results heightens competition in obesity marketAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
finance.yahoo.com - May 3 at 6:19 PM
Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?
stocknews.com - May 3 at 1:17 PM
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With ExpectationsPfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
msn.com - May 3 at 1:16 PM
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJs New Plan to Resolve Talc ClaimsPharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
finance.yahoo.com - May 3 at 1:16 PM
Vanguard Health Care Funds Strategic Moves in Q1 2024: A Focus on Pfizer IncVanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc
finance.yahoo.com - May 3 at 1:16 PM
Pfizer Inc. (NYSE:PFE) to Post FY2025 Earnings of $2.93 Per Share, Leerink Partnrs ForecastsPfizer Inc. (NYSE:PFE) to Post FY2025 Earnings of $2.93 Per Share, Leerink Partnrs Forecasts
marketbeat.com - May 3 at 12:53 PM
Heres Why Pfizer (PFE) is a Strong Momentum StockHere's Why Pfizer (PFE) is a Strong Momentum Stock
zacks.com - May 3 at 10:56 AM
Great Valley Advisor Group Inc. Trims Stake in Pfizer Inc. (NYSE:PFE)Great Valley Advisor Group Inc. Trims Stake in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 3 at 9:14 AM
NHS to provide Pfizer’s Voxelotor to treat sickle cell diseaseNHS to provide Pfizer’s Voxelotor to treat sickle cell disease
pharmaceutical-technology.com - May 3 at 8:16 AM
Q1 2024 Cardiff Oncology Inc Earnings CallQ1 2024 Cardiff Oncology Inc Earnings Call
finance.yahoo.com - May 3 at 8:16 AM
3 Ultra-Safe Stocks to Buy So You Can Rest Easy in Any Market3 Ultra-Safe Stocks to Buy So You Can Rest Easy in Any Market
investorplace.com - May 3 at 7:00 AM
Pfizer (NYSE:PFE) Shares Up 1.8% on Earnings BeatPfizer (NYSE:PFE) Shares Up 1.8% on Earnings Beat
americanbankingnews.com - May 3 at 2:12 AM
Fifth Third Bancorp Reduces Position in Pfizer Inc. (NYSE:PFE)Fifth Third Bancorp Reduces Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 3 at 12:41 AM
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid declinePfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid decline
msn.com - May 2 at 9:58 PM
Pfizer Prospects Garner Mixed Sentiment From Analysts: Finally, The Pivot Investors Have Been Waiting ForPfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
markets.businessinsider.com - May 2 at 9:58 PM
Pfizer (NYSE:PFE) Announces Quarterly  Earnings ResultsPfizer (NYSE:PFE) Announces Quarterly Earnings Results
marketbeat.com - May 2 at 4:04 PM
Pfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected EarningsPfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected Earnings
marketbeat.com - May 2 at 2:47 PM
Pfizer (NYSE:PFE) Price Target Raised to $29.00Pfizer (NYSE:PFE) Price Target Raised to $29.00
marketbeat.com - May 2 at 1:32 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Novo Nordisk A/S logo

Novo Nordisk A/S

NYSE:NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novartis logo

Novartis

NYSE:NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.